[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100420121":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":61,"collaborators":63,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":11,"enrollmentInfo":81,"targetDuration":11,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Kaiser Permanente","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral niacinamide","EXPERIMENTAL",null,[13],"Drug: Niacinamide",{"label":15,"type":16,"description":11,"interventionNames":17},"Matched placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Niacinamide","Niacinamide 3 grams on the day of surgery and post-surgical days one and two",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","Matched placebo on the day of surgery and post-surgical days one and two",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Ali Poyan Mehr, MD","CONTACT","4152644750","ali.x.poyanmehr@kp.org",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Kaiser Permanente San Francisco Medical Center","RECRUITING","San Francisco","California","94115","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-122.41942,37.77493,{"lat":48,"lon":47},[51,52,55,57,59],{"name":31,"role":32,"phone":11,"phoneExt":11,"email":11},{"name":53,"role":54,"phone":11,"phoneExt":11,"email":11},"Ahmad Sheikh, MD","SUB_INVESTIGATOR",{"name":56,"role":54,"phone":11,"phoneExt":11,"email":11},"Andrew Avins, MD",{"name":58,"role":54,"phone":11,"phoneExt":11,"email":11},"Lance Rtherford, MD",{"name":60,"role":54,"phone":11,"phoneExt":11,"email":11},"Paul LaPunzina, MD",{"type":62,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[64,67,69],{"name":65,"class":66},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"name":68,"class":6},"Beth Israel Deaconess Medical Center",{"name":70,"class":6},"Cedars-Sinai Medical Center","100420121","phase-2-nad-augmentation-in-cardiac-surgery-associated-myocardial-injury-trial-100420121",false,"NCT04750616","NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial","NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury (NACAM) Trial","NACAM","Inclusion Criteria\n\n* Informed consent before any study-related activities.\n* Men or women \\>18 years of age who are scheduled for non-emergent cardiac surgery procedures requiring CPB and are at increased risk for surgery-related adverse cardiovascular outcomes.\n\nProcedures include:\n\n* CABG\n* Aortic, mitral, tricuspid, or pulmonic valve replacement or repair\n* CABG with aortic, mitral, tricuspid, and\u002For pulmonic valve replacement\n\nRisk factors for surgery related to adverse cardiovascular outcomes include one or more of the following:\n\n* Valve surgery\n* eGFR \\\u003C 45 ml\u002Fmin\u002F1.73m2\n* Documented LVEF ≤ 35% within six months before surgery\n* Documented history of heart failure\n* Insulin-requiring diabetes\n* Non-insulin-requiring diabetes and the presence of ≥+2 proteinuria on urinalysis (or equivalent on urine protein-to-creatinine ratio or urine albumin-to-creatinine ratio)\n* Preoperative anemia (hemoglobin \\\u003C11g\u002Fdl for men and women)\n* History of prior CABG\n* Age ≥65\n\nExclusion Criteria\n\n* Preexisting AKI within seven days before surgery as defined by KDIGO stage ≥1 (serum creatinine-based)\n* Kidney transplant status\n* Off-pump cardiac surgery\n* ESRD\n* Emergent cardiac surgery\n* Pregnancy\n* Patient enrolled in competing research studies that may affect outcomes\n* Patients held in an institution by legal or official order","ALL","18 Years",{"count":82,"type":83},304,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery",[89,90,91],"Ischemia Reperfusion Injury","Myocardial Injury","Acute Kidney Injury","2025-03-10",{"date":94,"type":95},"2025-03-12","ACTUAL",{"date":97,"type":95},"2021-09-13",{"date":99,"type":83},"2025-06-30",{"name":5,"class":6},1]